A detailed history of Alyeska Investment Group, L.P. transactions in Evolus, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 325,000 shares of EOLS stock, worth $3.53 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
325,000
Previous 173,586 87.23%
Holding current value
$3.53 Million
Previous $1.88 Million 179.61%
% of portfolio
0.03%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.66 - $17.48 $1.61 Million - $2.65 Million
151,414 Added 87.23%
325,000 $5.27 Million
Q2 2024

Aug 14, 2024

BUY
$10.45 - $13.76 $1.81 Million - $2.39 Million
173,586 New
173,586 $1.88 Million
Q2 2020

Aug 14, 2020

BUY
$3.53 - $6.17 $129,381 - $226,142
36,652 Added 12.37%
332,977 $1.76 Million
Q1 2020

May 15, 2020

BUY
$3.53 - $12.21 $1.05 Million - $3.62 Million
296,325 New
296,325 $1.23 Million

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $609M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.